STOCK TITAN

Alzamend Neuro Inc - ALZN STOCK NEWS

Welcome to our dedicated news page for Alzamend Neuro (Ticker: ALZN), a resource for investors and traders seeking the latest updates and insights on Alzamend Neuro.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alzamend Neuro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alzamend Neuro's position in the market.

Rhea-AI Summary
Alzamend Neuro, Inc. (Nasdaq: ALZN) has received a 'Study May Proceed' letter from the FDA for the initiation of study AL001-PTSD01, a Phase IIA clinical study of AL001 for the treatment of patients with PTSD. The company aims to develop a next-generation lithium product (AL001) that would not routinely require therapeutic drug monitoring, constituting a major improvement over current lithium-based treatments. Alzamend has also received 'Study May Proceed' letters from the FDA for Phase IIA clinical studies of AL001 for the treatment of patients with BD, MDD, and PTSD in the last three months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
clinical trial
-
Rhea-AI Summary
Alzamend Neuro, Inc. (Nasdaq: ALZN) announces FDA approval to initiate Phase IIA clinical study of AL001 for treating major depressive disorder (MDD). The study aims to develop a next-generation lithium product that does not require therapeutic drug monitoring, potentially impacting 21 million Americans with MDD. The recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile, qualifying for a 505(b)(2) NDA pathway for FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.75%
Tags
clinical trial
-
Rhea-AI Summary
Alzamend Neuro, Inc. (Nasdaq: ALZN) has regained compliance with Nasdaq Listing Rule 5550(a)(2) after maintaining a closing bid price of at least $1.00 per share for ten consecutive trading days. The Compliance Notice from Nasdaq confirmed the closure of the matter, unrelated to the minimum Market Value of Listed Securities notice received earlier. Alzamend has until March 25, 2024, to comply with the MVLS Rule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
Rhea-AI Summary
Alzamend Neuro, Inc. (Nasdaq: ALZN) announced the completion of Phase IIA study of AL001 for Alzheimer’s patients and healthy subjects, showing a benign safety profile and identifying a candidate dose unlikely to require therapeutic drug monitoring. The company also submitted an IND application for a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for treatment of patients with PTSD, aiming to develop a next-generation lithium product that would not routinely require TDM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
clinical trial
-
Rhea-AI Summary
Alzamend Neuro, Inc. (ALZN) has announced a one-for-fifteen reverse stock split of its common stock. The split will be effective on October 31, 2023, and aims to regain compliance with the Minimum Bid Price Requirement of $1.00 per share to maintain listing on The Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1033.72%
Tags
none
-
Rhea-AI Summary
Alzamend Neuro has submitted an IND application to the FDA for a Phase IIA study of AL001 for the treatment of patients with major depressive disorder (MDD). AL001 is a novel lithium-delivery system that aims to provide the benefits of lithium while mitigating toxicities. The study may qualify for a 505(b)(2) NDA pathway for FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
clinical trial
Rhea-AI Summary
Alzamend Neuro receives FDA approval for Phase IIA clinical study of AL001 for BD type 1. Potential next-generation lithium product could improve treatment for 7 million Americans with BD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.44%
Tags
clinical trial
-
Rhea-AI Summary
Alzamend Neuro has received an extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement by November 15, 2023. The extension is subject to Alzamend obtaining stockholder approval for and effecting a reverse stock split by September 29, 2023, and maintaining a $1.00 closing bid price for ten consecutive business days. Alzamend intends to implement the split if stockholder approval is obtained.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
none
-
Rhea-AI Summary
Alzamend Neuro has submitted an IND application to the FDA for a Phase IIA study of AL001 for bipolar disorder. AL001 is a novel lithium-delivery system that aims to provide the benefits of lithium while avoiding toxicities. The maximum tolerated dose of AL001 is designed to distribute more lithium to the brain with improved safety compared to currently marketed lithium salts. Alzamend aims to replace a 300 mg TID lithium carbonate dose with a 240 mg TID AL001 lithium equivalent, representing a daily decrease of 20% of lithium. The program may qualify for the 505(b)(2) pathway for FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
clinical trial
Alzamend Neuro Inc

Nasdaq:ALZN

ALZN Rankings

ALZN Stock Data

5.99M
5.76M
28.58%
5.26%
0.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Tampa

About ALZN

alzamend neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer’s disease, bipolar disorder, major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”). our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ million americans suffering from these debilitating diseases. our current pipeline consists of two novel therapeutic drug candidates, al001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and alzn002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat alzheimer’s.